Takeo Fujii Selected Research

Trastuzumab (Herceptin)

1/2020	Prognostic Value of HER2 to CEP17 Ratio on Fluorescence In Situ Hybridization Ratio in Patients with Nonmetastatic HER2-Positive Inflammatory and Noninflammatory Breast Cancer Treated with Neoadjuvant Chemotherapy with or without Trastuzumab.
12/2018	Neoadjuvant Pertuzumab-containing Regimens Improve Pathologic Complete Response Rates in Stage II to III HER-2/neu-positive Breast Cancer: A Retrospective, Single Institution Experience.
1/2016	High HER2/Centromeric Probe for Chromosome 17 Fluorescence In Situ Hybridization Ratio Predicts Pathologic Complete Response and Survival Outcome in Patients Receiving Neoadjuvant Systemic Therapy With Trastuzumab for HER2-Overexpressing Locally Advanced Breast Cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Takeo Fujii Research Topics

Disease

18	Breast Neoplasms (Breast Cancer) 09/2021 - 01/2015
10	Neoplasms (Cancer) 10/2020 - 08/2003
6	Pathologic Complete Response 01/2020 - 01/2015
3	Neoplasm Metastasis (Metastasis) 01/2021 - 01/2018
3	Periodontitis 07/2008 - 06/2002
2	Circulating Neoplastic Cells 01/2020 - 01/2017
2	Disease Progression 07/2017 - 11/2016
1	Inflammatory Breast Neoplasms 01/2020
1	Lobular Carcinoma 01/2018
1	Pneumonia (Pneumonitis) 01/2018
1	Ductal Carcinoma 01/2018
1	Cardiotoxicity 11/2015
1	Cardiovascular Diseases (Cardiovascular Disease) 11/2015
1	Injection Site Reaction 01/2015
1	Rhabdomyolysis 08/2003
1	Periodontal Diseases (Periodontal Disease) 06/2003
1	Periodontal Pocket (Periodontal Pockets) 06/2002
1	Bone Resorption 06/2002

Drug/Important Bio-Agent (IBA)

7	Hormones (Hormone)IBA 10/2020 - 12/2015
4	Biomarkers (Surrogate Marker)IBA 10/2018 - 01/2017
3	Trastuzumab (Herceptin)FDA Link 01/2020 - 01/2016
3	Androgen Receptors (Androgen Receptor)IBA 09/2017 - 11/2016
3	Proteins (Proteins, Gene)FDA Link 07/2017 - 06/2003
3	AnthracyclinesIBA 12/2015 - 01/2015
2	ErbB Receptors (EGF Receptor)IBA 10/2020 - 01/2016
2	Biological ProductsIBA 01/2018 - 07/2017
2	Estrogen ReceptorsIBA 01/2017 - 11/2016
2	Interleukin-6 (Interleukin 6)IBA 06/2003 - 06/2002
1	Cytotoxins (Cytolysins)IBA 09/2021
1	EnzymesIBA 01/2021
1	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 01/2021
1	ChromatinIBA 01/2021
1	MTOR InhibitorsIBA 10/2020
1	Capecitabine (Xeloda)FDA Link 10/2020
1	Epithelial Cell Adhesion MoleculeIBA 01/2020
1	Radium-223IBA 01/2020
1	pertuzumabIBA 12/2018
1	Epidermal Growth Factor (EGF)IBA 12/2018
1	Immune Checkpoint InhibitorsIBA 10/2018
1	Cell-Free Nucleic AcidsIBA 07/2017
1	Messenger RNA (mRNA)IBA 07/2017
1	LigandsIBA 07/2017
1	AntibodiesIBA 01/2017
1	Keratins (Keratin)IBA 01/2017
1	DAPIIBA 01/2017
1	Fluoxymesterone (Halotestin)FDA Link 11/2016
1	Indicators and Reagents (Reagents)IBA 01/2016
1	Isocitrate Dehydrogenase (Isocitrate Dehydrogenase (NAD+))IBA 01/2016
1	Cyclophosphamide (Cytoxan)FDA LinkGeneric 12/2015
1	PlatinumIBA 12/2015
1	Methotrexate (Mexate)FDA LinkGeneric 12/2015
1	Fluorouracil (Carac)FDA LinkGeneric 12/2015
1	Docetaxel (Taxotere)FDA Link 12/2015
1	taxaneIBA 12/2015
1	Pharmaceutical PreparationsIBA 11/2015
1	Doxorubicin (Adriamycin)FDA LinkGeneric 11/2015
1	Epirubicin (Ellence)FDA LinkGeneric 11/2015
1	liposomal doxorubicin (Doxil)FDA Link 11/2015
1	fosaprepitant FDA Link 01/2015
1	Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor)IBA 07/2008
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 06/2003
1	CytokinesIBA 06/2003
1	Interleukin-8 (Interleukin 8)IBA 06/2003
1	InterleukinsIBA 06/2003
1	Interleukin-1beta (Interleukin 1 beta)IBA 06/2003
1	bone resorption factorIBA 06/2002
1	LipopolysaccharidesIBA 06/2002

Therapy/Procedure

10	Therapeutics 09/2021 - 12/2015
7	Neoadjuvant Therapy 01/2020 - 01/2015
4	Drug Therapy (Chemotherapy) 10/2020 - 01/2015
2	Immunotherapy 01/2018 - 01/2018
1	Time-to-Treatment 07/2017
1	Adjuvant Chemotherapy 12/2015
1	Treatment Delay 11/2015
1	Nephrectomy 08/2003
1	Nephroureterectomy 08/2003